

Extraordinary Report

March 23 , 2018

(TRANSLATION)

Note for readers of this English translation

On March 23, 2018, Chugai Pharmaceutical Co., LTD. (the “Company”) filed its Japanese-language Extraordinary Report (Rinji Houkokusho) (the “Report”) with the Director-General of the Kanto Financial Bureau in Japan in connection with the Company's shareholders' voting results for proposals acted upon at the 107th Annual General Meeting of Shareholders held on March 22, 2018 pursuant to the Financial Instruments and Exchange Act of Japan. This document is an English translation of the Report.

1. Reason for submitting the Extraordinary Report

Given that resolutions were made for the proposals at the 107th Annual General Meeting of Shareholders (the “Meeting”) held on March 22, 2018, Chugai Pharmaceutical Co., Ltd (the “Company”) submits this Extraordinary Report under the provisions of Article 24-5, Paragraph 4, of the Financial Instruments and Exchange Act of Japan and Article 19, Paragraph 2, Item 9-2, of the Cabinet Office Ordinance on Disclosure of Corporate Information, etc.

2. Contents of the Extraordinary Report

(1) Date when the Meeting was held: March 22, 2018

(2) Matters for resolution**Proposal 1 Appropriation of Surplus**

Year-end dividend

JPY 33 per share of common stock of the Company

Proposal 2 Election of Five (5) Directors

Osamu Nagayama, Motoo Ueno, Tatsuro Kosaka, Yasuo Ikeda, Sophie Kornowski-Bonnet were elected as directors of the Company.

(3) Number of voting rights concerning the indication of "for", "against" or "abstention" for each proposal; and Requirements for approving the proposals; Results of resolutions

| Proposal | For | Against | Abstention | Ratio of favorable votes | Results |
|-------------------------|-----------|---------|------------|--------------------------|----------|
| Proposal 1 | 5,063,945 | 265 | 75 | 99.53% | Approved |
| Proposal 2 | | | | | |
| Osamu Nagayama | 4,756,745 | 293,650 | 13,914 | 93.49% | Approved |
| Motoo Ueno | 5,033,792 | 30,450 | 75 | 98.94% | Approved |
| Tatsuro Kosaka | 4,781,648 | 268,747 | 13,914 | 93.98% | Approved |
| Yasuo Ikeda | 5,028,670 | 35,569 | 75 | 98.84% | Approved |
| Sophie Kornowski-Bonnet | 5,042,679 | 21,563 | 75 | 99.11% | Approved |

Notes: Requirements for the approval of each proposal are as follows.

- 1) The resolution for Proposal 1 must be adopted by a majority of the votes of the shareholders present at the Meeting, who are entitled to exercise voting rights.
- 2) The resolution for Proposals 2 must be adopted by a majority of the votes of the shareholders present at the Meeting where the number of the voting rights of the shareholders present, amounts to one-third (1/3) or more.

(4) Reason why a portion of the voting rights held by the shareholders present at the Meeting held on March 22, 2018 was not added to the number of voting rights

Because in terms of Japanese Companies Act, the required majority approval for each proposal was met by the votes exercised prior to the Meeting held on March 22, 2018, as well as the votes exercised by a portion of shareholders present and confirmed by the Company at the Meeting held on March 22, 2018; the voting rights of the shareholders present at the Meeting held on March 22, 2018, untraceable with the final decision of "for" "against" or "abstention" as to each proposal are not tallied.